



July 30, 2026

Company Name	LinqMed Inc.
Representative	Yukie Yoshii, President and CEO

Phase I Clinical Trial Results of ^{64}Cu -ATSM Radioligand Therapy for Recurrent Malignant Brain Tumors Published in ESMO Open, a Peer-Reviewed Journal

LinqMed Inc. ("LinqMed" or the "Company"; Head Office: Chiba City, Chiba Prefecture, Japan; President and Chief Executive Officer: Yukie Yoshii) announces that the results of the Phase I STAR-64 clinical trial of the radioligand therapy ^{64}Cu -ATSM in patients with recurrent malignant brain tumors have been published in ESMO Open, a peer-reviewed international journal of the European Society for Medical Oncology.

The publication reports the results of the world's first clinical trial involving the administration of ^{64}Cu -ATSM to patients as a therapeutic agent. Publication in ESMO Open, a peer-reviewed journal, indicates that the study findings have undergone a rigorous peer-review process and have been published as clinical data supporting the continued development of this program.

Publication Details

Title

First-in-human phase I study of hypoxia-targeting ^{64}Cu -ATSM radioligand therapy in patients with malignant brain tumors (STAR-64)

Journal

ESMO Open

DOI : 10.1016/j.esmoop.2026.108249

Article URL

<https://www.sciencedirect.com/science/article/pii/S2059702926021915>

End

About LinqMed

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative “visible” anti-cancer treatments to patients. Our mission is “Link for Life -Linking Innovative Science and Medicine for Your Health and Happiness”. LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope ^{64}Cu , which can be used for diagnosis and therapy, simultaneously.

URL : <https://linqmed.net/>

Inquiries:

LinqMed Inc.

Email: linqmed@linqmed.co.jp